From President Helene Saam
20th HAE Patient Meeting: On 18 May 2019, the 20th Patient Meeting of HAE Switzerland took place in Bern. Approximately 50 interested HAE patients, relatives, doctors, representatives of the pharmaceutical companies and guests participated at the Novotel Hotel. HAE experts filled the morning with exciting lectures and our guest speaker, the HAE International Executive Vice President & COO Henrik Balle Boysen gave us an insight into the worldwide HAE work. It was very gratifying to hear from him that the future looks good for HAE sufferers. And indeed, a lot of research and various drug studies are running. Our Patient Meeting rounded off with a very interesting tour through the production facility of CSL Behring Bern in the afternoon. A big thank you to the two pharma companies for sponsoring our meeting.
Takhzyro in Switzerland: The pharmaceutical company Takeda Pharma AG has on 6 June 2019 received approval for the new drug Takhzyro from SwissMedic and thus this drug is available from September 2019 in Switzerland. Takhzyro can be used in patients over the age of 12 years to prevent HAE attacks. This medicine contains the active substance lanadelumab and is administered subcutaneously as a prophylaxis. Further information on the new drug can be found at www.haevereinigung.ch.
Preview next dates: On 8 November 2019, we have the 18th Swiss HAE General Meeting and on 20 June 2020 it is time for the HAE Patient Meeting in Zurich with HAE expert lectures as well as a guided tour of the TV studios of SRFF.
HAE Care Center information: The HAE International map has been updated with fresh information on HAE Care Centers in Switzerland – please see https://haei.org/hae-member-countries/switzerland.
